Learn more Servier has signed an agreement to acquire Edgewise Therapeutics’ muscular dystrophy business in a deal valued at ...
Under the agreement, Servier will pay $1.55 billion upfront, with up to an additional $1.1 billion tied to regulatory and ...
Edgewise Therapeutics (EWTX) stays a Buy after its $2.65B Servier deal funds EDG-7500 for HCM with key Q2 2026 data. Read ...
France-based pharma company Servier is acquiring the muscular dystrophy business of Edgewise Therapeutics as part of a ...
In addition to the upfront fee, Servier has committed up to $1.1 billion in regulatory and commercial milestones to acquire ...
The French pharma firm Servier is buying an experimental muscular dystrophy drug from Edgewise Therapeutics for $1.55 billion ...
Parents of children diagnosed with Duchenne muscular dystrophy are meeting with Georgian Prime Minister Irakli Kobakhidze at ...
Servier has signed the largest licensing deal in its history, paying $1.55 billion upfront for Edgewise Therapeutics' ...
Orphan Drug Designation (ODD) recognizes Duchenne muscular dystrophy as a rare disease with significant unmet medical need ...
A trio of deals from Eli Lilly, Servier, and Avenzo highlights continued industry investment in rare diseases and oncology, ...
When Dean Burkin, Ph.D., first began studying Duchenne muscular dystrophy (DMD), the goal was straightforward and urgent: ...
Doctors once believed that Lily Brasch would not live past age 4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results